Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.

Journal Article (Clinical Trial;Letter;Multicenter Study)

Full Text

Duke Authors

Cited Authors

  • Cornell, R; Hari, P; Tang, S; Biran, N; Callander, N; Chari, A; Chhabra, S; Fiala, MA; Gahvari, Z; Gandhi, U; Godby, K; Gupta, R; Jagannath, S; Jagosky, M; Kang, Y; Kansagra, A; Kauffman, M; Kodali, S; Kumar, SK; Lakshman, A; Liedtke, M; Lonial, S; Ma, X; Malek, E; Mansour, J; McGehee, EF; Neppalli, A; Paul, B; Richardson, P; Scott, EC; Shacham, S; Shah, J; Siegel, DS; Umyarova, E; Usmani, SZ; Varnado, W; Vij, R; Costa, L

Published Date

  • January 2021

Published In

Volume / Issue

  • 96 / 1

Start / End Page

  • E5 - E8

PubMed ID

  • 32974944

Electronic International Standard Serial Number (EISSN)

  • 1096-8652

Digital Object Identifier (DOI)

  • 10.1002/ajh.26010

Language

  • eng

Conference Location

  • United States